All In Biotech

Drug Trial Radar · NCT00003240

Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer

A Major Randomised Trial to Determine the Value of Cisplatin-Based Chemotherapy For All Patients With Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Dec 18, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 1,800 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,800

Planned (sponsor's estimate)

Start

Oct 1995

Primary completion

Not stated

Sponsor

Sponsor type
NIH
First posted
Feb 20, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not known whether giving chemotherapy in addition to standard therapy is a more effective treatment for lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of standard therapy given with or without combination chemotherapy in treating patients with non-small cell lung cancer.

Conditions

  • Lung Cancer

Interventions

  • cisplatinDrug

  • ifosfamideDrug

  • mitomycin CDrug

  • vinblastine sulfateDrug

  • vindesineDrug

  • vinorelbine tartrateDrug

  • conventional surgeryProcedure

  • radiation therapyRadiation

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Middlesex Hospital- Meyerstein Institute

    London, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.